about
Primary hepatic carcinoid tumoursThe apoptotic response of liver and colorectal liver metastases to focal hyperthermic injury.Effect of blood flow occlusion on laser hyperthermia for liver metastases.Interstitial laser thermotherapy in the treatment of colorectal liver metastases.Effect of interstitial laser hyperthermia in a murine model of colorectal liver metastases.Effect of interstitial laser hyperthermia in a murine model of colorectal liver metastases: scanning electron microscopic study.Progressive microvascular injury in liver and colorectal liver metastases following laser induced focal hyperthermia therapy.Patterns of heat shock protein (HSP70) expression and Kupffer cell activity following thermal ablation of liver and colorectal liver metastases.Mechanisms of focal heat destruction of liver tumors.Altered growth patterns of colorectal liver metastases after thermal ablation.Impact of blood flow occlusion on liver necrosis following thermal ablation.Alterations in vascular architecture and permeability following OXi4503 treatment.Changes in growth factor levels after thermal ablation in a murine model of colorectal liver metastasesSpatial morphological and molecular differences within solid tumors may contribute to the failure of vascular disruptive agent treatments.From minimal to maximal surgery in the treatment of hepatocarcinoma: A reviewTreatment with the vascular disruptive agent OXi4503 induces an immediate and widespread epithelial to mesenchymal transition in the surviving tumor.Aneurysms of the splenic artery - a review.Focal intrahepatic strictures: a review of diagnosis and management.Outcomes of patients with histologically proven acute acalculous cholecystitis.Sex differences and outcomes of management of acute cholecystitis.Lymphatics and colorectal liver metastases: the case for sentinel node mapping.Early Outcome of Liver Resections in Octogenarians.Styrene maleic acid copolymer-pirarubicin induces tumor-selective oxidative stress and decreases tumor hypoxia as possible treatment of colorectal cancer liver metastases.Assessment of Liver Remnant Using ICG Clearance Intraoperatively during Vascular Exclusion: Early Experience with the ALIIVE TechniqueMetabolic response to preoperative chemotherapy predicts prognosis for patients undergoing surgical resection of colorectal cancer metastatic to the liver.In vitro and in vivo evaluation of tumor targeting styrene-maleic acid copolymer-pirarubicin micelles: Survival improvement and inhibition of liver metastases.Hyperbaric oxygen therapy and liver transplantation.Vascular targeting agent Oxi4503 inhibits tumor growth in a colorectal liver metastases model.Liver regeneration stimulates tumor metastases.Comparison of 3 Methodologies for Genotyping of Small Deletion and Insertion Polymorphisms.The prognostic significance of lymphatics in colorectal liver metastasesHyperbaric oxygen therapy reduces the severity of ischaemia, preservation and reperfusion injury in a rat model of liver transplantation.Outcomes of cholecystectomy for treatment of acute cholecystitis in octogenarians.The effect of hyperbaric oxygen on apoptosis and proliferation in severe acute pancreatitis.Percutaneous cholecystostomy for treatment of acute cholecystitis in the era of early laparoscopic cholecystectomy.Results of pancreatic resection associated with portal vein resection in an Australian tertiary care centre.Outcomes after identical and compatible orthotopic liver transplantation for fulminant hepatic failure: a single center experience in UK.A fast track recovery program significantly reduces hospital length of stay following uncomplicated pancreaticoduodenectomy.Styrene maleic acid-pirarubicin disrupts tumor microcirculation and enhances the permeability of colorectal liver metastases.Serum carbohydrate antigen 19-9 in pancreatic adenocarcinoma: a mini review for surgeons.
P50
Q28272261-1A781B2B-9E1B-4798-AAA4-1839F7B8D688Q30783113-725550B7-DC60-4CA8-BD7B-B40799ED6090Q30829087-7D3943E3-805C-49CE-A13A-001600CA71BFQ30982302-629BBD47-EF54-4111-A50A-5A0877A3199CQ31089300-0333C1AC-451D-4A55-ABD9-ECBE1CD43E28Q33195492-D514EA1E-6E82-413D-804D-B01B9EB55BBFQ33217046-A82D5E01-61DA-41A5-861F-16204C605414Q33219522-6B58A66F-D360-432E-BCDD-7CFF0CFEA7A3Q33221211-DE677F75-6839-48CF-BD07-C7F9FA2A8C4FQ33229907-C725163D-34C8-42E8-9637-A79D98F153FDQ33234134-8A16D3E0-C1E2-4EF3-9ECE-6533749A0A0EQ33307486-2DFAE1C2-8C05-4383-B0A9-024C6C8EAE4EQ33850209-5E1676D3-8442-44DB-A1D6-D6A9B4C4A0EEQ34478450-24418EEA-C7AF-4C09-A8FA-1F78E9B31074Q34966860-7985B1CE-B64D-4440-9511-F27C0CAC6381Q37482536-16B7C26E-BCDF-4C21-AD3E-456EA4765756Q37766999-85AA925C-C9FC-46C4-BBD8-DFFA0FBA3C8AQ38016592-E56B3FA8-9959-433A-A549-FB3309493793Q38040173-957B098B-D771-4B90-B5EE-435BF1925074Q38079535-377E33B8-01BC-4EEA-8C3A-D41B979E27A1Q38122755-AA922324-6207-4C42-9E80-1379D6D2511AQ38653769-C282AAE9-64E1-4B92-B2E8-DC9DDFC38204Q38872151-68B5D2DB-926C-4570-AA6F-7D0D1E8DCE1CQ38992142-5E206145-9211-48ED-9853-776D9C98C1D7Q39238789-79859296-7358-4503-9B80-7A5B9A067DD6Q39688233-8825DB94-0759-4824-AD61-968005FA0570Q39721640-CC483F2A-8C50-4C6E-9A35-ABCE0C42FDC8Q40121939-87423176-17FA-4E7E-852C-1772DBEF535BQ40179022-7B1AF605-17A2-4097-BB3F-3525D3AC5390Q40385646-25FEBFDF-E47D-445B-A00C-56EDB243CC61Q40619916-7CA2EFE7-696F-496C-A718-80719521AD1EQ41013255-5144E949-5FCD-4DCC-8606-B7DF1F393CFDQ42611882-291F6AC1-8B4B-45D1-A39A-DCAC4CAB8401Q42945553-83CC9536-1DE1-46CA-960F-7B28813ACD1DQ43638653-04D85586-0645-45FD-A64B-C7ACD71C895BQ43884259-971F9028-7F20-4529-9DF5-8441737C17D8Q44925956-29325A02-2D9B-4BAB-8B07-6935A407C542Q45730557-69A98A55-E991-472D-A3D9-B7B517977602Q46294414-48A238B9-76BD-4E60-AD86-09280A44F693Q48248436-9CBEC228-F22B-469D-933F-F4868642815A
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Vijayaragavan Muralidharan
@ast
Vijayaragavan Muralidharan
@en
Vijayaragavan Muralidharan
@es
Vijayaragavan Muralidharan
@nl
Vijayaragavan Muralidharan
@sl
type
label
Vijayaragavan Muralidharan
@ast
Vijayaragavan Muralidharan
@en
Vijayaragavan Muralidharan
@es
Vijayaragavan Muralidharan
@nl
Vijayaragavan Muralidharan
@sl
prefLabel
Vijayaragavan Muralidharan
@ast
Vijayaragavan Muralidharan
@en
Vijayaragavan Muralidharan
@es
Vijayaragavan Muralidharan
@nl
Vijayaragavan Muralidharan
@sl
P106
P31
P496
0000-0001-8247-8937